BEIJING, May 26 (Xinhua) -- AliHealth (00241.HK), the healthcare flagship of Alibaba Group, reported 20.58 billion yuan (about 3.1 billion U.S. dollars) of revenue in the fiscal year 2022, a year-on-year increase of 32.6 percent, reported China Securities Journal on Wednesday.
Revenue from its self-operated pharmaceutical businesses rose 35.5 percent year on year to 17.91 billion yuan. Among them, pharmaceutical products contributed 64 percent and the prescription drug business saw its revenue surge by 105.2 percent year on year.
It is noteworthy that AliHealth saw a sharp year-on-year increase of 98.9 percent in its healthcare and digital service businesses during the period.
The company continued to expand supply-side product categories to support businesses on e-commerce platforms, including the Tmall pharmaceutical platform, which has served over 26,000 merchants.
Besides, AliHealth has achieved multiple breakthroughs in the healthcare service business, attracting another 170 million active users to Alipay's healthcare channel by the end of March this year.
(Edited by Dai Jingjing with Xinhua Silk Road, aime_jenny@163.com)
A single purchase
